周期性発熱症候群の世界市場

周期性発熱症候群の世界市場は2030年までに7億4,560万米ドルに達する見込み

2024年に6億1,880万米ドルと推定される周期性発熱症候群の世界市場は、2030年には7億4,560万米ドルに達し、分析期間2024～2030年のCAGRは3.2%で成長すると予測されます。本レポートで分析したセグメントの1つである高免疫グロブリン血症D症候群は、CAGR 4.0％を記録し、分析期間終了時には3億4,650万米ドルに達すると予測されます。家族性地中海熱症候群セグメントの成長率は、分析期間中CAGR 1.7%と推定されます。

米国市場は推定1億6,860万米ドル、中国はCAGR6.1％で成長予測

米国の周期性発熱症候群市場は、2024年に1億6,860万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億4,810万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.4%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の周期性発熱症候群市場- 主要動向と促進要因まとめ

周期性発熱症候群の特徴と誤診されやすい理由とは？

周期性発熱症候群は、感染を伴わない発熱と全身性炎症の再発を特徴とする、まれな自己炎症性疾患群です。PFAPA（周期性発熱、アフタ性口内炎、咽頭炎、腺炎）、家族性地中海熱（FMF）、TRAPS（TNF受容体関連周期性症候群）などのこれらの症候群は、一般的に小児期に発症し、自然免疫系を制御する遺伝子の変異に関連しています。

感染症や自己免疫疾患と症状が重複するため、誤診が多いです。認知度が高まるにつれ、より正確な臨床的認識と遺伝子検査により、臨床医は再発性発熱の原因を感染症、自己免疫疾患、自己炎症性疾患と区別できるようになってきています。まれではあるが、これらの症候群は生活の質、就学、介護者の負担に重大な影響を及ぼすため、早期診断と長期的なケア計画が必要です。

遺伝学と免疫学の進歩により、診断と治療はどのように進歩しているのでしょうか？

遺伝性周期性発熱症候群の確認には、遺伝子検査が中心的な役割を果たしています。MEFV、TNFRSF1A、その他の関連遺伝子の変異を同定するために、標的化次世代シークエンス（NGS）パネルやエクソームシークエンスが三次医療施設で使用されるようになってきています。バイオマーカー研究、特にインターロイキン-1（IL-1）経路の関与が治療決定の指針となっています。

治療法はサブタイプによって異なります。FMFではコルヒチンが標準治療であり、PFAPAではコルチコステロイドがしばしば用いられます。IL-1（例、アナキンラ、カナキヌマブ）およびTNF-αを標的とする生物学的製剤は、難治性または遺伝的に確認された症候群で使用されることが多くなっています。疾患修飾戦略は、長期的な臓器障害を最小限に抑えながら、発作の頻度と重症度を減少させることを目的としています。

臨床の焦点はどこに移り、どの利害関係者が調査に投資しているのか？

診断と治療の主要な場は、大学病院と小児リウマチセンターです。北米と欧州では、全国的な希少疾患登録と共同研究ネットワークが、周期性発熱症候群の臨床的・遺伝的特徴の解明を支援しています。FMFがより多くみられる中東や地中海地域では、地域的な認識やスクリーニングプログラムが強化されています。

製薬会社は、希少疾病用医薬品に指定された希少症候群をターゲットに、自己炎症性疾患の生物学的療法に投資しています。遺伝子診断企業は、小児の自己炎症性疾患に焦点を当てたパネルを開発し、早期介入を可能にしています。患者支援団体は、専門医による治療や生物学的製剤による治療へのアクセスを改善するため、臨床医や政策立案者の認知度向上に努めています。

周期性発熱症候群市場の成長はいくつかの要因によって牽引されています。

周期性発熱症候群市場の成長は、自己炎症性疾患の認知度向上、遺伝子検査へのアクセス拡大、標的生物学的療法の利用拡大などの要因によって牽引されます。診断アルゴリズムの改善、小児医療におけるシークエンシングの広範な応用により、稀な発熱性症候群の早期かつ正確な特定につながっています。

希少疾病用医薬品に対する規制上の優遇措置や、IL-1阻害剤やTNF阻害剤の適応拡大が、バイオファーマの投資を促しています。長時間作用型の生物製剤の開発や、希少疾患教育プログラムによる臨床医の意識の向上が、市場の成長をさらに後押ししています。患者登録や国境を越えた研究イニシアティブが成熟するにつれて、周期性発熱症候群はより体系的な臨床上の注目を集めるようになり、この専門分野における技術革新と市場拡大を後押ししています。

セグメント

症候群（高免疫グロブリン血症D症候群、家族性地中海熱症候群、TNF受容体関連周期性症候群、クリオピリン関連周期性症候群、その他の症候群）;治療（経口抗炎症薬、非ステロイド性抗炎症薬D、抗TNF療法、スタチン治療、その他の治療）;エンドユーザー（病院エンドユーザー、小売薬局エンドユーザー）

調査対象企業の例

• AbbVie Inc.
• AB2 Bio Ltd
• Amgen Inc.
• AstraZeneca plc
• BioCryst Pharmaceuticals
• Boehringer Ingelheim
• Bristol Myers Squibb
• Chugai Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Horizon Therapeutics（Amgen）
• InnoCare Pharma
• Kiniksa Pharmaceuticals
• Novartis AG
• Olatec Therapeutics LLC
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Sanofi
• Sobi（Swedish Orphan Biovitrum）
• Takeda Pharmaceutical Company

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Periodic Fever Syndrome Market to Reach US$745.6 Million by 2030

The global market for Periodic Fever Syndrome estimated at US$618.8 Million in the year 2024, is expected to reach US$745.6 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. HyperimmunoGlobulinemia D syndrome, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$346.5 Million by the end of the analysis period. Growth in the Familial Mediterranean Fever Syndrome segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.6 Million While China is Forecast to Grow at 6.1% CAGR

The Periodic Fever Syndrome market in the U.S. is estimated at US$168.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$148.1 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Periodic Fever Syndrome Market - Key Trends & Drivers Summarized

What Characterizes Periodic Fever Syndromes and Why Are They Often Misdiagnosed?

Periodic fever syndromes are a group of rare, autoinflammatory disorders characterized by recurrent episodes of fever and systemic inflammation without infection. These syndromes, such as PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis), Familial Mediterranean Fever (FMF), and TRAPS (TNF Receptor-Associated Periodic Syndrome), typically present in childhood and are linked to mutations in genes regulating the innate immune system.

Misdiagnosis is common due to symptom overlap with infections or autoimmune diseases. As awareness grows, more accurate clinical recognition and genetic testing are helping clinicians differentiate between infectious, autoimmune, and autoinflammatory causes of recurrent fevers. Although rare, these syndromes have significant impacts on quality of life, school attendance, and caregiver burden, prompting early diagnosis and long-term care planning.

How Is Diagnosis and Treatment Progressing with Advancements in Genetics and Immunology?

Genetic testing plays a central role in confirming hereditary periodic fever syndromes. Targeted next-generation sequencing (NGS) panels and exome sequencing are increasingly used in tertiary centers to identify mutations in MEFV, TNFRSF1A, and other related genes. Biomarker studies, particularly interleukin-1 (IL-1) pathway involvement, are guiding treatment decisions.

Treatment approaches vary by subtype. Colchicine is the standard therapy for FMF, while corticosteroids are often used in PFAPA. Biologic therapies targeting IL-1 (e.g., anakinra, canakinumab) and TNF-alpha are increasingly used in refractory or genetically confirmed syndromes. Disease-modifying strategies aim to reduce attack frequency and severity while minimizing long-term organ damage.

Where Is the Clinical Focus Shifting and Which Stakeholders Are Investing in Research?

Academic hospitals and pediatric rheumatology centers are primary settings for diagnosis and care. In North America and Europe, national rare disease registries and collaborative research networks are supporting deeper clinical and genetic characterization of periodic fever syndromes. In the Middle East and Mediterranean regions, where FMF is more prevalent, regional awareness and screening programs are being strengthened.

Pharmaceutical companies are investing in biologic therapies for autoinflammatory diseases, targeting rare syndromes with orphan drug designations. Genetic diagnostics firms are developing panels focused on pediatric autoinflammatory conditions, enabling earlier intervention. Patient advocacy organizations are working to increase recognition among clinicians and policy makers to improve access to specialist care and biologic therapies.

Growth in the Periodic Fever Syndrome market is driven by several factors…

Growth in the periodic fever syndrome market is driven by factors such as increased recognition of autoinflammatory diseases, expanding access to genetic testing, and greater availability of targeted biologic therapies. Improved diagnostic algorithms, along with broader application of sequencing in pediatric medicine, are leading to earlier and more accurate identification of rare febrile syndromes.

Regulatory incentives for orphan drugs and expanded indications for IL-1 and TNF inhibitors are encouraging biopharma investment. Development of long-acting biologics and increased clinician awareness through rare disease education programs are further supporting market growth. As patient registries and cross-border research initiatives mature, periodic fever syndromes are receiving more structured clinical attention, driving innovation and market expansion in this specialized segment.

SCOPE OF STUDY:

The report analyzes the Periodic Fever Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Syndrome (HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome, Other Syndromes); Treatment (Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy, Statins Treatment, Other Treatments); End-Use (Hospitals End-Use, Retail Pharmacy End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AbbVie Inc.
• AB2 Bio Ltd
• Amgen Inc.
• AstraZeneca plc
• BioCryst Pharmaceuticals
• Boehringer Ingelheim
• Bristol Myers Squibb
• Chugai Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Horizon Therapeutics (Amgen)
• InnoCare Pharma
• Kiniksa Pharmaceuticals
• Novartis AG
• Olatec Therapeutics LLC
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Sanofi
• Sobi (Swedish Orphan Biovitrum)
• Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Periodic Fever Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis Rates of Autoinflammatory Disorders Spurs Demand for Targeted Treatments for Periodic Fever Syndromes
  • Increased Genetic Testing Capabilities Strengthen Early Identification and Classification of Hereditary Fever Disorders
  • Growth in Pediatric Rheumatology Awareness Throws the Spotlight on Underdiagnosed Recurrent Fever Conditions
  • Expansion of Biologic Therapies and IL-1 Inhibitors Supports Clinical Management of Resistant Cases
  • OEM Investment in Orphan Drug Development Encourages Pipeline Growth for Rare Autoinflammatory Indications
  • Advancements in Next-Generation Sequencing (NGS) Enhance Detection of Mutations in MEFV, TNFRSF1A, and Related Genes
  • Global Expansion of Autoinflammatory Disease Registries Improves Clinical Understanding and Therapeutic Strategy Development
  • Rising Adoption of Precision Medicine Supports Individualized Treatment Pathways in PFAPA and CAPS Patients
  • Pediatric Specialist Training and Referral Networks Promote Timely Diagnosis and Long-Term Disease Monitoring
  • Integration of Telehealth and Remote Monitoring Tools Facilitates Management of Flare Frequency and Response Tracking
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Periodic Fever Syndrome Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Periodic Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for HyperimmunoGlobulinemia D syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for HyperimmunoGlobulinemia D syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for HyperimmunoGlobulinemia D syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Familial Mediterranean Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Familial Mediterranean Fever Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Familial Mediterranean Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for TNF Receptor-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for TNF Receptor-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for TNF Receptor-Associated Periodic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Cryopyrin-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Cryopyrin-Associated Periodic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Cryopyrin-Associated Periodic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Syndromes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Syndromes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Syndromes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oral Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oral Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Oral Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Anti-TNF Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Anti-TNF Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Anti-TNF Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Statins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Statins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Statins Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacy End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Retail Pharmacy End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Retail Pharmacy End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Periodic Fever Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Periodic Fever Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Periodic Fever Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Periodic Fever Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Periodic Fever Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Periodic Fever Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Periodic Fever Syndrome by Syndrome - HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Periodic Fever Syndrome by Syndrome - Percentage Breakdown of Value Sales for HyperimmunoGlobulinemia D syndrome, Familial Mediterranean Fever Syndrome, TNF Receptor-Associated Periodic Syndrome, Cryopyrin-Associated Periodic Syndrome and Other Syndromes for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Periodic Fever Syndrome by Treatment - Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Periodic Fever Syndrome by Treatment - Percentage Breakdown of Value Sales for Other Treatments, Oral Anti-Inflammatory Drugs, Non-Steroidal Anti-Inflammatory Drugs, Anti-TNF Therapy and Statins Treatment for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Periodic Fever Syndrome by End-Use - Hospitals End-Use and Retail Pharmacy End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Periodic Fever Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Retail Pharmacy End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION